References
- Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch. Dis. Child.90, 2–7 (2005).
- Polanczyk G, de Lima MS, Horta BL, Biederman J, Rhode LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry164, 942–948 (2007).
- Swanson JM, Sergeant JA, Taylor E, Sonuga-Barke EJ, Jensen PS, Cantwell DP. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet351, 429–433 (1998).
- Coghill D, Soutullo C, d’Aubuisson C et al. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child. Adolesc. Psychiatry Ment. Health2, 31 (2008).
- Noe L, Hankin CS. Health outcomes of childhood attention-deficit/hyperactivity disorder (ADHD): health care use and work status of caregivers. Value Health4, 142–143 (2001).
- Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J. Pediatr. Psychol.32, 711–727 (2007).
- Hakkaart-Van Roijen L, Zwirs BW, Bouwmans C et al. Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur. Child Adolesc. Psychiatry16, 316–326 (2007).
- Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O’Brien PC. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA285, 60–66 (2001).
- Sax L, Kautz KJ. Who first suggests the diagnosis of attention-deficit/hyperactivity disorder? Ann. Fam. Med.1, 171–174 (2003).
- German Society for Child and Adolescent Psychiatry and Psychotherapy. Guidelines for the Diagnosis and Treatment of Mental Disorders in Infancy, Childhood and Adolescence. German Medical Publishers, Köln, Germany, 239–254 (2007).
- Taylor E, Döpfner M, Sergeant J et al. European clinical guidelines for hyperkinetic disorder – first upgrade. Eur. Child Adolesc. Psychiatry13(Suppl. 1), I7–30 (2004).
- Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs17(2), 117–131 (2003).
- Jahng KH, Martin LR, Golin CE, DiMatteo MR. Preferences for medical collaboration: patient–physician congruence and patient outcomes. Patient Educ. Couns.57, 308–314 (2005).
- Sluijs E, van Dulmen S, van Dijk L, de Ridder D, Heerdink R, Bensing J. Patient Adherence to Medical Treatment: A Meta Review. Nivel, Utrecht, The Netherlands (2006).
- Kiesler DJ, Auerbach SM. Optimal matches of patient preferences for information, decision-making and interpersonal behavior: evidence, models and interventions. Patient Educ. Couns.61, 319–341 (2006).
- DosReis S, Mychailyszyn MP, Evans-Lacko SE, Beltran A, Riley AW, Myers MA. The meaning of attention-deficit/hyperactivity disorder medication and parents’ initiation and continuity of treatment for their child. J. Child Adolesc. Psychopharmacol.19(4), 377–383 (2009).
- Ryan M, Gerard K, Amaya-Amaya M. Using Discrete Choice Experiments to Value Health and Health Care, The Economics of Non-Market Goods and Resources. Springer, Dordrecht, Germany (2008).
- Lancsar E, Louviere J. Conducting discrete choice experiments to inform health care decision making: a user’s guide. Pharmacoeconomics26(8), 661–677 (2008).
- Bryan S, Parry D. Structural reliability of conjoint measurement in health care: an empirical investigation. Appl. Econ.34, 561–567 (2001).
- Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients’ preferences for the management of non-metastatic prostate cancer: discrete choice experiment. Br. Med. J.328(7436), 382 (2004).
- Mühlbacher AC, Lincke HJ, Nübling M. Evaluating patients’ preferences for multiple myeloma therapy, a discrete-choice-experiment. Psychosoc. Med.5, 10 (2008).
- Phillips KA, Maddala T, Johnson FR. Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Services Res.37, 1681–1705 (2002).
- Roux L, Ubach C, Donaldson C, Ryan M. Valuing the benefits of weight loss programs: an application of the discrete choice experiment. Obesity Res.12, 1342–1351 (2004).
- Hauber AB, Johnson FR, Sauriol L, Lescrauwaet B. Risking health to avoid injections: preferences of Canadians with Type 2 diabetes. Diabetes Care28(9), 2243–2245 (2005).
- Johnson FR, Manjunath R, Mansfield CA, Clayton LJ, Hoerger TJ, Zhang P. High-risk individuals’ willingness to pay for diabetes risk-reduction programs. Diabetes Care29(6), 1351–1356 (2006).
- Hauber AB, Johnson FR, Mohamed AF, Leibman C, Arrighi HM, Grundman M. Older Americans’ risk-benefit preferences for modifying the course of Alzheimer’s disease. Alzheimer Dis. Assoc. Disord.23(1), 23–32 (2009).
- Mühlbacher AC, Rudolph I, Lincke HJ, Nübling M. Preferences for treatment of attention-deficit/hyperactivity disorder (ADHD): a discrete choice experiment. BMC Health Serv. Res.9, 149 (2009).
- Mühlbacher AC, Nübling M. Analysis of patients’ preferences. Direct assessment and discrete-choice experiment of therapy in adults with attention-deficit hyperactivity disorder (ADHD). Patient3(4), 1–10 (2010).
- American Academy of Pediatrics. Clinical Practice Guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics105, 1158–1170 (2000).
- Wolraich ML, Wibbelsman CJ, Browne TE et al. Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics115, 1734–1746 (2005).
- Van Brunt K, Matza LS, Classi PM, Johnston JA. Preferences related to attention-deficit/hyperactivity disorder and its treatment. Patient Preferences Adherence5, 33–43 (2011).
- Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy29(6), 656–679 (2009).
- Sinzig J, Morsch D, Lehmkuhl G. Do hyperactivity, impulsivity and inattention have an impact on the ability of facial affect recognition in children with autism and ADHD? Eur. Child Adolesc. Psychiatry17(2), 63–72 (2008).
- Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry63(Suppl. 12), 10–15 (2002).
- Guevremont DC, Dumas MC. Peer relationship problems and disruptive behavior disorders. J. Emot. Behav. Dis.2, 164–172 (1994).
- Normand S, Schneider BH, Robaey P. Attention-deficit/hyperactivity disorder and the challenges of close friendship. J. Can. Acad. Child Adolesc. Psychiatry16(2), 67–73 (2007).
- Hoza B, Mrug S, Gerdes AC et al. What aspects of peer relationships are impaired in children with attention-deficit/hyperactivity disorder? J. Consult. Clin. Psychol.73(3), 411–423 (2005).
- Mrug S, Hoza B, Gerdes AC et al. Discriminating between children with ADHD and classmates using peer variables. J. Atten. Disord.12(4), 372–380 (2009).
- Wåhlstedt C, Thorell LB, Bohlin G. ADHD symptoms and executive function impairment: early predictors of later behavioral problems. Dev. Neuropsychol.33(2), 160–178 (2008).
- Kanning U. [Diagnostics of Social Competences: Compendium – Psychological Diagnostics]. Hogrefe, Göttingen, Germany (2009).
- Connor DF, Edwards G, Fletcher KE, Baird J, Barkley RA, Steingard RJ. Correlates of comorbid psychopathology in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry42, 193–200 (2003).
Websites
- National Institute for Health and Clinical Excellence (NICE): Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. NICE clinical guideline 72 (2008) www.nice.org.uk/nicemedia/live/12061/42059/42059.pdf
- Burgess L. Discrete choice experiments (computer software). Department of Mathematical Sciences, University of Technology, Sydney (2007) http://crsu.science.uts.edu.au/choice/
- EMEA: Questions and answers on the review of medicines containing methylphenidate (22 January 2009), Doc. Ref. EMEA/658285/2008 www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Methylphenidate_31/WC500011125.pdf